Researchers investigated the mechanisms of lung cancer's earliest stages. A new protein discovery could help in the treatment and early detection of lung cancer. Researchers at the University of Edinburgh found that the protein TLR2 regulates several of the body's defensive processes in response to carcinogenic cellular changes. The study's results are published in the journal Cell Reports under the title "Toll-like receptor 2 orchestrates a tumor suppressor response in non-small cell lung cancer."
“„Targeting early-stage lung cancer is vital to improve survival. However, the mechanisms and components of the early tumor suppressor response in lung cancer are not well understood. In this report, we study the role of Toll-like receptor 2 (TLR2), a regulator of oncogene-induced senescence, which is a key tumor suppressor response in premalignancy. Using human lung cancer samples and genetically engineered mouse models, we show that TLR2 is active early in lung tumorigenesis, where it correlates with improved survival and clinical regression.- Abstract Of The Said Study
“„I think these results are really exciting. Very little is known about the biology of early lung cancer and by understanding this process more we have identified a possible new treatment for this devastating disease. This project highlights the value of basic science research and how this can be translated into new treatments for patients.- Dr. Fraser Millar, University of Edinburgh
Lung Cancer: Early Diagnosis, Treatment